Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2462MR)

This product GTTS-WQ2462MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000885.6; NM_000889.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695
UniProt ID P13612; P26010
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2462MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3532MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ321MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 19D12
GTTS-WQ13474MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ10308MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LJM716
GTTS-WQ4942MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ15061MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ13749MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ13420MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRO132365
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW